RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:证据不足
北京时间·🕒 发布 20:45:27·⟳ 抓取 21:00:21 +14m54s·⚡ 决策 10-08 21:02:16 +1m55s·19.2 天前
Editas Medicine 获澳大利亚监管与伦理批准，启动 EDIT-401 治疗高胆固醇的首次人体 I/II 期试验
官方新闻稿确认了 FIH 批准这一正面状态迁移，但该进展是公司此前已披露 CTN 申报与年内给药计划后的预期内节点；距首个真实人体安全性数据尚有约一个季度以上，盘前仅小幅上涨且量极小，缺乏可交易的短期正预期差。
📄 原文RTTNews Biotech↗ 原文
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Editas Medicine, Inc.（EDIT.US）
FIH 批准为预期内的早期去风险里程碑，近期无人体数据、催化空窗至 2027Q1，盘前仅小幅温和反应，短线预期差与赔率不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
EDIT-401 进入首次人体试验对 Editas 是积极的管线去风险，但属于预期内的早期里程碑，2027Q1 才有人体数据，短期催化力度和赔率不足，故不做。
消息传播链
- 公司官方宣布获澳大利亚批准启动 EDIT-401 首次人体 Strive I/II 期试验，维持年内给药计划。
- RTTNews 转述并补充试验设计、五个澳新中心及数据时间线；盘前股价约 2.80 美元、涨约 1.8%，反应温和。市场反应:EDIT 盘前约 +2%，成交量极小，未见显著重估。
关键理由
- EDIT-401 从临床前推进至 I/II 期，验证了体内 LDLR 编辑路径的监管可行性并打开 HeFH 大患者池期权。
- 临床前约 90% 的 LDL-C 降幅及十个月持久性为管线提供了较强的生物学先验。
主要风险
- I 期早期安全性尚不确定，首个真实人体数据要到 2027Q1，期间催化空窗、股价易受现金消耗与板块情绪影响。
- FIH 批准基本落在公司既定 CTN 申报与年内给药节奏内，新增 surprise 有限，盘前量能也未显示资金重估。
反向证据
先例如何影响了这次决策
对本次决策的影响:先例不足与事件本身预期内、近期无数据读出共同支持放弃，而非以小仓试探。
方向:未构建可信的同市场、同相位（早期 FIH 批准）对齐先例面板，不能据以设定幅度。
涨幅量级:缺乏锚点干净的 aligned 先例，无法校准 I 期启动类催化的短线涨幅。
形态:无足够先例判断见光死概率；盘前温和小涨与低量仅作现场观察，不作为统计结论。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 28 ms
{"result": "search_processed_events:agent query=`editas edit-401 australia first-in-human approval hyperlipidemia | editas strive trial phase 1/2 ldlr gene editing hefh regulatory approval`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续 - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - web_search 成功 doubao_search · 1,847 ms
豆包搜索结果（原始查询:Editas EDIT-401 Strive trial Australia approval first-in-human hyperlipidemia press release；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,022 ms
{
原文全文
展开原文 · 9,820 字
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
By
TajSabreen Ahamed
✉
Published:
10/8/2026 8:45 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Editas Medicine, Inc. (
EDIT
) has received regulatory and ethics approval in Australia to begin the first-in-human Phase 1/2 clinical trial of EDIT-401, an experimental gene editing therapy designed to treat hyperlipidemia, or high levels of LDL cholesterol.
The company remains on track to start dosing patients later this year.
Hyperlipidemia is a major risk factor for heart disease, heart attack, and stroke. The initial trial will focus on patients with Heterozygous Familial Hypercholesterolemia (HeFH), an inherited condition that causes very high LDL cholesterol levels from an early age. An estimated 1.2 million people in the United States are living with HeFH, many of whom remain undiagnosed.
EDIT-401 is an in vivo gene-editing medicine designed to directly modify the LDLR gene, which plays a key role in removing LDL cholesterol from the bloodstream. By increasing LDL receptor activity, the therapy aims to deliver long-lasting reductions in LDL cholesterol levels with a single treatment.
The Phase 1/2 Strive trial will evaluate the safety, tolerability, and effectiveness of a single dose of EDIT-401. The study consists of two parts. Part 1 is an open-label, single ascending-dose, dose-finding study designed to identify appropriate dose levels, while Part 2 is a randomized, placebo-controlled expansion study that will further assess the therapy's safety and efficacy. Editas has selected five clinical trial sites across Australia and New Zealand.
Preclinical studies have shown encouraging results. According to the company, EDIT-401 achieved approximately 90% or greater average reductions in LDL cholesterol, lipoprotein (a), and ApoB in non-human primates. Additional data demonstrated that LDL cholesterol reductions of about 90% were maintained for up to ten months in an ongoing study.
Editas expects to report initial safety and tolerability data from the trial in the first quarter of 2027, with topline safety and efficacy results from the dose-finding portion of the study expected later in 2027.
The company also plans to present new preclinical durability data for EDIT-401 at American Heart Association (AHA) Scientific Sessions 2026, in November.
The approval marks an important milestone for Editas Medicine as it advances its gene-editing
technology
into human testing for cardiovascular disease, expanding beyond rare genetic disorders into a much larger patient population.
EDIT has traded between $1.66 and $4.33 over the past year. The stock closed Wednesday's trading at $2.75, up 0.73%. In pre-market trading, the stock is at $2.80, up 1.82%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
U.S. Stocks Close Mostly Higher Amid Sharp Pullback By Crude Oil
September 25, 2026 16:27 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
Editas Medicine Names Dan Ory Chief Medical Officer
Editas Posts Narrower Loss In Q2, Expects Phase 1/2 Data For EDIT-401 In Q1 Of '27; Stock Up
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
Futures Point To Open Lower
October 08, 2026 08:24 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
No Dangerous Infectious Disease Detected Among Russia Lab Worker Contacts: WHO
October 07, 2026 08:48 ET
French, Japanese Chemists Win Nobel Prize For Solving Molecular Mystery
October 07, 2026 08:42 ET
'Rising Temperatures Mean Rising Danger In Pregnancy,' UNFCCC Chief Warns
October 07, 2026 08:19 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
By
TajSabreen Ahamed
✉
Published:
10/8/2026 8:45 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Editas Medicine, Inc. (
EDIT
) has received regulatory and ethics approval in Australia to begin the first-in-human Phase 1/2 clinical trial of EDIT-401, an experimental gene editing therapy designed to treat hyperlipidemia, or high levels of LDL cholesterol.
The company remains on track to start dosing patients later this year.
Hyperlipidemia is a major risk factor for heart disease, heart attack, and stroke. The initial trial will focus on patients with Heterozygous Familial Hypercholesterolemia (HeFH), an inherited condition that causes very high LDL cholesterol levels from an early age. An estimated 1.2 million people in the United States are living with HeFH, many of whom remain undiagnosed.
EDIT-401 is an in vivo gene-editing medicine designed to directly modify the LDLR gene, which plays a key role in removing LDL cholesterol from the bloodstream. By increasing LDL receptor activity, the therapy aims to deliver long-lasting reductions in LDL cholesterol levels with a single treatment.
The Phase 1/2 Strive trial will evaluate the safety, tolerability, and effectiveness of a single dose of EDIT-401. The study consists of two parts. Part 1 is an open-label, single ascending-dose, dose-finding study designed to identify appropriate dose levels, while Part 2 is a randomized, placebo-controlled expansion study that will further assess the therapy's safety and efficacy. Editas has selected five clinical trial sites across Australia and New Zealand.
Preclinical studies have shown encouraging results. According to the company, EDIT-401 achieved approximately 90% or greater average reductions in LDL cholesterol, lipoprotein (a), and ApoB in non-human primates. Additional data demonstrated that LDL cholesterol reductions of about 90% were maintained for up to ten months in an ongoing study.
Editas expects to report initial safety and tolerability data from the trial in the first quarter of 2027, with topline safety and efficacy results from the dose-finding portion of the study expected later in 2027.
The company also plans to present new preclinical durability data for EDIT-401 at American Heart Association (AHA) Scientific Sessions 2026, in November.
The approval marks an important milestone for Editas Medicine as it advances its gene-editing
technology
into human testing for cardiovascular disease, expanding beyond rare genetic disorders into a much larger patient population.
EDIT has traded between $1.66 and $4.33 over the past year. The stock closed Wednesday's trading at $2.75, up 0.73%. In pre-market trading, the stock is at $2.80, up 1.82%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
U.S. Stocks Under Pressure As Crude Oil Prices, Treasury Yields Surge
September 28, 2026 11:06 ET
U.S. Stocks Close Mostly Higher Amid Sharp Pullback By Crude Oil
September 25, 2026 16:27 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol
Editas Medicine Names Dan Ory Chief Medical Officer
Editas Posts Narrower Loss In Q2, Expects Phase 1/2 Data For EDIT-401 In Q1 Of '27; Stock Up
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
Futures Point To Open Lower
October 08, 2026 08:24 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
No Dangerous Infectious Disease Detected Among Russia Lab Worker Contacts: WHO
October 07, 2026 08:48 ET
French, Japanese Chemists Win Nobel Prize For Solving Molecular Mystery
October 07, 2026 08:42 ET
'Rising Temperatures Mean Rising Danger In Pregnancy,' UNFCCC Chief Warns
October 07, 2026 08:19 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
275a07f13d· 2026-10-08 21:02 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前